The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study

BACKGROUND: Dupilumab is an antibody against interleukin‐4 receptor α, used in the treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate‐to‐severe AD. METHODS: In this randomized, double‐blind, placebo‐controlled, pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Y., Wu, L., Lu, Q., Gao, X., Zhu, X., Yao, X., Li, L., Li, W., Ding, Y., Song, Z., Liu, L., Dang, N., Zhang, C., Liu, X., Gu, J., Wang, J., Geng, S., Liu, Q., Guo, Y., Dong, L., Su, H., Bai, L., O’Malley, J.T., Luo, J., Laws, E., Mannent, L., Ruddy, M., Amin, N., Bansal, A., Ota, T., Wang, M., Zhang, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298048/
https://www.ncbi.nlm.nih.gov/pubmed/34358343
http://dx.doi.org/10.1111/bjd.20690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298048/
https://www.ncbi.nlm.nih.gov/pubmed/34358343
http://dx.doi.org/10.1111/bjd.20690

Ejemplares similares